表达 IL7/CCL19 的 CAR-T 细胞在胶质母细胞瘤和胰腺癌难治性实体瘤模型中的治疗疗效

Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.

体外及卵巢癌小鼠异种移植模型中对胶质母细胞瘤、乳腺癌和胰腺癌有效的嵌合抗原受体 (CAR)-NK92 细胞

Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of o

我们的结果表明，CD44v6-CAR-NK92 细胞可能是一种有吸引力的治疗实体瘤的治疗剂。

放疗预处理增强 B7-H3-CAR-T 治疗实体瘤模型的疗效

Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.

我们的结果提示，B7-H3-CAR-T 疗法联合放疗可能是治疗实体瘤的一种有前景的方式。

双特异性 c-Met/PD-1 CAR-T 细胞对实体瘤具有增强的治疗效果

Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor.

靶向 IL-13Rα2 的肿瘤免疫治疗最新进展

Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.

三级淋巴结构通过重塑冷肿瘤微环境实现从冷到热的转变

Tertiary lymphoid structures achieve 'cold' to 'hot' transition by remodeling the cold tumor microenvironment.

2009 至 2021 年 CAR-T 细胞的文献计量学与知识图谱分析

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.

作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法，CAR-T 细胞疗法仍处于快速发展阶段。CAR-T 细胞相关领域在未来仍将是研究热点。

肿瘤浸润 NK 细胞的扰动组学

Perturbomics of tumor-infiltrating NK cells.

在实体瘤中激活模式识别受体以产生全身性抗肿瘤免疫

Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.